DE10208313A1 - Ambroxol für die Behandlung von schmerzhaften Zuständen im Mund und Rachenraum - Google Patents
Ambroxol für die Behandlung von schmerzhaften Zuständen im Mund und RachenraumInfo
- Publication number
- DE10208313A1 DE10208313A1 DE10208313A DE10208313A DE10208313A1 DE 10208313 A1 DE10208313 A1 DE 10208313A1 DE 10208313 A DE10208313 A DE 10208313A DE 10208313 A DE10208313 A DE 10208313A DE 10208313 A1 DE10208313 A1 DE 10208313A1
- Authority
- DE
- Germany
- Prior art keywords
- throat
- mouth
- ambroxol
- pain
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 31
- JBDGDEWWOUBZPM-XYPYZODXSA-N ambroxol Chemical compound NC1=C(Br)C=C(Br)C=C1CN[C@@H]1CC[C@@H](O)CC1 JBDGDEWWOUBZPM-XYPYZODXSA-N 0.000 title claims abstract description 24
- 229960005174 ambroxol Drugs 0.000 title claims abstract description 23
- 239000003814 drug Substances 0.000 claims abstract description 9
- 150000003839 salts Chemical class 0.000 claims abstract description 7
- 238000004519 manufacturing process Methods 0.000 claims abstract description 6
- 210000003800 pharynx Anatomy 0.000 claims description 19
- QNVKOSLOVOTXKF-UHFFFAOYSA-N 4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol;hydron;chloride Chemical compound Cl.NC1=C(Br)C=C(Br)C=C1CNC1CCC(O)CC1 QNVKOSLOVOTXKF-UHFFFAOYSA-N 0.000 claims description 16
- 229960000985 ambroxol hydrochloride Drugs 0.000 claims description 16
- 201000007100 Pharyngitis Diseases 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 208000009889 Herpes Simplex Diseases 0.000 claims description 7
- 208000002399 aphthous stomatitis Diseases 0.000 claims description 7
- 208000007565 gingivitis Diseases 0.000 claims description 7
- 208000028169 periodontal disease Diseases 0.000 claims description 7
- 238000001356 surgical procedure Methods 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000003765 sweetening agent Substances 0.000 claims description 5
- 108091005804 Peptidases Proteins 0.000 claims description 4
- 102000035195 Peptidases Human genes 0.000 claims description 4
- 239000013543 active substance Substances 0.000 claims description 4
- 239000003242 anti bacterial agent Substances 0.000 claims description 4
- 230000002421 anti-septic effect Effects 0.000 claims description 4
- 229940088710 antibiotic agent Drugs 0.000 claims description 4
- 229940064004 antiseptic throat preparations Drugs 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 235000003599 food sweetener Nutrition 0.000 claims description 4
- 239000000314 lubricant Substances 0.000 claims description 4
- 230000009854 mucosal lesion Effects 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 239000011782 vitamin Substances 0.000 claims description 4
- 229940088594 vitamin Drugs 0.000 claims description 4
- 235000013343 vitamin Nutrition 0.000 claims description 4
- 229930003231 vitamin Natural products 0.000 claims description 4
- 239000011159 matrix material Substances 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 230000001857 anti-mycotic effect Effects 0.000 claims description 2
- 239000002543 antimycotic Substances 0.000 claims description 2
- 206010031009 Oral pain Diseases 0.000 claims 1
- 210000003300 oropharynx Anatomy 0.000 abstract description 6
- 239000000902 placebo Substances 0.000 description 23
- 239000007937 lozenge Substances 0.000 description 22
- 229940068196 placebo Drugs 0.000 description 21
- 230000000694 effects Effects 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 230000037406 food intake Effects 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 230000001741 anti-phlogistic effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 239000007967 peppermint flavor Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- -1 2-amino-3,5-dibromo-benzyl Chemical group 0.000 description 2
- JBDGDEWWOUBZPM-UHFFFAOYSA-N 4-[(2-amino-3,5-dibromophenyl)methylamino]-1-cyclohexanol Chemical compound NC1=C(Br)C=C(Br)C=C1CNC1CCC(O)CC1 JBDGDEWWOUBZPM-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 229940121357 antivirals Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229960003511 macrogol Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 229940085605 saccharin sodium Drugs 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- IYLLULUTZPKQBW-UHFFFAOYSA-N Acrinol Chemical compound CC(O)C(O)=O.C1=C(N)C=CC2=C(N)C3=CC(OCC)=CC=C3N=C21 IYLLULUTZPKQBW-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- UDKCHVLMFQVBAA-UHFFFAOYSA-M Choline salicylate Chemical compound C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O UDKCHVLMFQVBAA-UHFFFAOYSA-M 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 235000004866 D-panthenol Nutrition 0.000 description 1
- 239000011703 D-panthenol Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 244000166124 Eucalyptus globulus Species 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 240000002657 Thymus vulgaris Species 0.000 description 1
- 235000007303 Thymus vulgaris Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960001716 benzalkonium Drugs 0.000 description 1
- CYDRXTMLKJDRQH-UHFFFAOYSA-N benzododecinium Chemical compound CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 CYDRXTMLKJDRQH-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229960004830 cetylpyridinium Drugs 0.000 description 1
- NEUSVAOJNUQRTM-UHFFFAOYSA-N cetylpyridinium Chemical compound CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 NEUSVAOJNUQRTM-UHFFFAOYSA-N 0.000 description 1
- 229960002688 choline salicylate Drugs 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 229960000840 dequalinium Drugs 0.000 description 1
- PCSWXVJAIHCTMO-UHFFFAOYSA-P dequalinium Chemical compound C1=CC=C2[N+](CCCCCCCCCC[N+]3=C4C=CC=CC4=C(N)C=C3C)=C(C)C=C(N)C2=C1 PCSWXVJAIHCTMO-UHFFFAOYSA-P 0.000 description 1
- 229960003949 dexpanthenol Drugs 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229960004189 ethacridine lactate Drugs 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229960004716 idoxuridine Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 230000000510 mucolytic effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- RARSHUDCJQSEFJ-UHFFFAOYSA-N p-Hydroxypropiophenone Chemical compound CCC(=O)C1=CC=C(O)C=C1 RARSHUDCJQSEFJ-UHFFFAOYSA-N 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960002800 prednisolone acetate Drugs 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000012487 rinsing solution Substances 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 235000021092 sugar substitutes Nutrition 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000001585 thymus vulgaris Substances 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 229940126307 triamcinolone acetate Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Nutrition Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Physiology (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (25)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10208313A DE10208313A1 (de) | 2002-02-27 | 2002-02-27 | Ambroxol für die Behandlung von schmerzhaften Zuständen im Mund und Rachenraum |
| TW092103899A TW200306804A (en) | 2002-02-27 | 2003-02-25 | Ambroxol for the treatment of painful conditions in the mouth and pharyngeal cavity |
| JP2003570840A JP2005518435A (ja) | 2002-02-27 | 2003-02-25 | 口腔及び咽頭腔における疼痛状態の治療用アンブロキソール |
| BR0308038-2A BR0308038A (pt) | 2002-02-27 | 2003-02-25 | Ambroxol para o tratamento de estados doloridos na cavidade bucal e faringe |
| RU2004129284/15A RU2311176C2 (ru) | 2002-02-27 | 2003-02-25 | Амброксол для лечения болей в полости рта и глотки |
| AU2003210345A AU2003210345B2 (en) | 2002-02-27 | 2003-02-25 | Ambroxol for treating painful conditions in the mouth and pharyngeal cavity |
| CA002477105A CA2477105A1 (en) | 2002-02-27 | 2003-02-25 | Ambroxol for the treatment of painful conditions in the mouth and pharyngeal cavity |
| MYPI20030651A MY144781A (en) | 2002-02-27 | 2003-02-25 | Ambroxol for the treatment of painful conditions in the mouth and pharyngeal cavity |
| MXPA04008220A MXPA04008220A (es) | 2002-02-27 | 2003-02-25 | Ambroxol para tratamiento de estados dolorosos en cavidad bucal y faringea. |
| UA20040907789A UA86741C2 (ru) | 2002-02-27 | 2003-02-25 | Амброксол для лечения боли в полости рта и глотки |
| PL03371584A PL371584A1 (en) | 2002-02-27 | 2003-02-25 | Ambroxol for treating painful conditions in the mouth and pharyngeal cavity |
| PCT/EP2003/001886 WO2003072094A1 (de) | 2002-02-27 | 2003-02-25 | Ambroxol für die behandlung von schmerzhaften zuständen im mund und rachenraum |
| CNA038047683A CN1638749A (zh) | 2002-02-27 | 2003-02-25 | 用于治疗口腔及咽腔疼痛症状的氨溴索 |
| EP03742955A EP1480626A1 (de) | 2002-02-27 | 2003-02-25 | Ambroxol für die behandlung von schmerzhaften zuständen im mund und rachenraum |
| KR10-2004-7013393A KR20040084944A (ko) | 2002-02-27 | 2003-02-25 | 구강 및 인두강의 통증 상태 치료용 암브록솔 |
| UY27679A UY27679A1 (es) | 2002-02-27 | 2003-02-25 | Ambroxol para el tratamiento de estados dolorosos en la cavidad bucal y faríngea. |
| PE2003000187A PE20030830A1 (es) | 2002-02-27 | 2003-02-26 | Ambroxol para el tratamiento de estados dolorosos en la cavidad bucal y faringea |
| ARP030100619A AR038698A1 (es) | 2002-02-27 | 2003-02-26 | Ambroxol para el tratamiento de estados dolorosos en la cavidad bucal y faringea |
| US10/376,349 US20030166732A1 (en) | 2002-02-27 | 2003-02-27 | Ambroxol for the treatment of painful conditions in the mouth and pharyngeal cavity |
| ZA200405635A ZA200405635B (en) | 2002-02-27 | 2004-07-15 | Ambroxol for treating painfull conditions in the mouth and pharyngeal cavity. |
| IS7417A IS7417A (is) | 2002-02-27 | 2004-08-19 | Ambroxól til að meðhöndla kvalafullt ástand í munni og koki |
| EC2004005242A ECSP045242A (es) | 2002-02-27 | 2004-08-20 | Ambroxol para el tratamiento de estados dolorosos en la cavidad bucal y faríngea |
| US11/185,558 US20050256193A1 (en) | 2002-02-27 | 2005-07-20 | Ambroxol for the treatment of painful conditions in the mouth and pharyngeal cavity |
| US11/751,245 US20070224267A1 (en) | 2002-02-27 | 2007-05-21 | Ambroxol for the treatment of painful conditions in the mouth and pharyngeal cavity |
| US12/861,163 US20100330176A1 (en) | 2002-02-27 | 2010-08-23 | Ambroxol for the treatment of painful conditions in the mouth and pharyngeal cavity |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10208313A DE10208313A1 (de) | 2002-02-27 | 2002-02-27 | Ambroxol für die Behandlung von schmerzhaften Zuständen im Mund und Rachenraum |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE10208313A1 true DE10208313A1 (de) | 2003-09-11 |
Family
ID=27740434
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE10208313A Withdrawn DE10208313A1 (de) | 2002-02-27 | 2002-02-27 | Ambroxol für die Behandlung von schmerzhaften Zuständen im Mund und Rachenraum |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP1480626A1 (enExample) |
| JP (1) | JP2005518435A (enExample) |
| KR (1) | KR20040084944A (enExample) |
| CN (1) | CN1638749A (enExample) |
| AR (1) | AR038698A1 (enExample) |
| AU (1) | AU2003210345B2 (enExample) |
| BR (1) | BR0308038A (enExample) |
| CA (1) | CA2477105A1 (enExample) |
| DE (1) | DE10208313A1 (enExample) |
| EC (1) | ECSP045242A (enExample) |
| IS (1) | IS7417A (enExample) |
| MX (1) | MXPA04008220A (enExample) |
| MY (1) | MY144781A (enExample) |
| PE (1) | PE20030830A1 (enExample) |
| PL (1) | PL371584A1 (enExample) |
| RU (1) | RU2311176C2 (enExample) |
| TW (1) | TW200306804A (enExample) |
| UA (1) | UA86741C2 (enExample) |
| UY (1) | UY27679A1 (enExample) |
| WO (1) | WO2003072094A1 (enExample) |
| ZA (1) | ZA200405635B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10332486A1 (de) * | 2003-07-16 | 2005-02-10 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ambroxol für die Behandlung akuter Schmerzen |
| JP2005120063A (ja) * | 2003-10-14 | 2005-05-12 | Boehringer Ingelheim Pharma Gmbh & Co Kg | 咽頭における炎症の治療のためのアンブロキソール |
| ITMI20032462A1 (it) * | 2003-12-16 | 2005-06-17 | Advance Holdings Ltd | Metodo per preparare una caramella contenente ambroxolo e la caramella cosi' ottenuta |
| DE102004021992A1 (de) * | 2004-05-03 | 2005-11-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Topische Zubereitung enthaltend Ambroxol |
| JP2007084471A (ja) * | 2005-09-21 | 2007-04-05 | Sunstar Inc | 口腔用組成物および口腔用製品の選択方法 |
| EP2015761A4 (en) * | 2006-03-29 | 2009-07-29 | Naveh Pharma 1996 Ltd | METHOD AND COMPOSITION FOR THE TREATMENT OF NUTRITIONAL IGNITION |
| JP5765934B2 (ja) * | 2009-12-28 | 2015-08-19 | サンスター株式会社 | 口腔用組成物 |
| JP6171683B2 (ja) * | 2012-08-03 | 2017-08-02 | 大正製薬株式会社 | 固形製剤 |
| CN105769908B (zh) * | 2016-05-06 | 2019-03-01 | 湖北凤凰白云山药业有限公司 | 一种化痰止咳的药物及其制备方法 |
| CN109982692A (zh) | 2016-11-14 | 2019-07-05 | 王明武 | 用于治疗眼表疾病的制剂和相关方法 |
| CN106727621A (zh) * | 2016-11-22 | 2017-05-31 | 郑州仁宏医药科技有限公司 | 一种治疗牙痛的西药散剂 |
| JP6844394B2 (ja) * | 2017-04-14 | 2021-03-17 | 大正製薬株式会社 | 固形組成物 |
| EP3415143A1 (en) | 2017-06-16 | 2018-12-19 | Kai-Uwe Kern | Bromhexine for the treatment of pain |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3432411A1 (de) * | 1983-09-17 | 1985-04-11 | Dr. Karl Thomae Gmbh, 7950 Biberach | Antiadhaesive prohylactica und arzneimittel, enthaltend ein sekretolytisch wirksames benzylaminderivat |
| DE3445226A1 (de) * | 1983-12-14 | 1985-08-01 | Reifenrath, Rainer Richard Otto, Dr.med., 7920 Heidenheim | Pharmazeutisches erzeugnis zur behandlung und prophylaxe von infektionen sowie von husten und obstruktiven atemwegserkrankungen |
| DE4415553A1 (de) * | 1994-05-03 | 1995-11-09 | Behringwerke Ag | Verwendung von Deoxyspergualin zur Herstellung eines Arzneimittels zur Behandlung von entzündlich-hyperreaktiven Erkrankungen |
| DE19933148A1 (de) * | 1999-07-20 | 2001-01-25 | Boehringer Ingelheim Int | Ambroxolhaltige Lutschtablette |
| DE20102817U1 (de) * | 2000-02-23 | 2001-06-07 | Bolder Arzneimittel GmbH, 50968 Köln | Lutsch- und Kaupastillen mit Cyclodextrin |
| WO2002045714A1 (en) * | 2000-12-04 | 2002-06-13 | The Procter & Gamble Company | Drug formulation having improved oral tolerability |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3034975C2 (de) * | 1980-09-17 | 1986-11-27 | Dr. Karl Thomae Gmbh, 7950 Biberach | Arzneimittelkombination zur Behandlung infektiöser Atemwegerkrankungen |
| US5122540A (en) * | 1986-02-28 | 1992-06-16 | W. Keith R. Watson | Method and composition for treating warts and throat soreness with DMSO and citric acid |
| US5458879A (en) * | 1994-03-03 | 1995-10-17 | The Procter & Gamble Company | Oral vehicle compositions |
| CA2253260A1 (en) * | 1996-05-02 | 1997-11-13 | Taisho Pharmaceutical Co., Ltd. | Suspension of sparingly water-soluble acidic drug |
| JP2001151677A (ja) * | 1999-11-26 | 2001-06-05 | Taisho Pharmaceut Co Ltd | 咽頭用組成物 |
| RU2169557C1 (ru) * | 1999-12-22 | 2001-06-27 | Александр Афанасьевич Яремчук | Сироп амброксола для лечения бронхопульмональных заболеваний |
-
2002
- 2002-02-27 DE DE10208313A patent/DE10208313A1/de not_active Withdrawn
-
2003
- 2003-02-25 CA CA002477105A patent/CA2477105A1/en not_active Abandoned
- 2003-02-25 UY UY27679A patent/UY27679A1/es not_active Application Discontinuation
- 2003-02-25 TW TW092103899A patent/TW200306804A/zh unknown
- 2003-02-25 KR KR10-2004-7013393A patent/KR20040084944A/ko not_active Ceased
- 2003-02-25 AU AU2003210345A patent/AU2003210345B2/en not_active Ceased
- 2003-02-25 MY MYPI20030651A patent/MY144781A/en unknown
- 2003-02-25 CN CNA038047683A patent/CN1638749A/zh active Pending
- 2003-02-25 UA UA20040907789A patent/UA86741C2/ru unknown
- 2003-02-25 WO PCT/EP2003/001886 patent/WO2003072094A1/de not_active Ceased
- 2003-02-25 MX MXPA04008220A patent/MXPA04008220A/es not_active Application Discontinuation
- 2003-02-25 EP EP03742955A patent/EP1480626A1/de not_active Ceased
- 2003-02-25 PL PL03371584A patent/PL371584A1/xx not_active Application Discontinuation
- 2003-02-25 RU RU2004129284/15A patent/RU2311176C2/ru not_active IP Right Cessation
- 2003-02-25 JP JP2003570840A patent/JP2005518435A/ja active Pending
- 2003-02-25 BR BR0308038-2A patent/BR0308038A/pt not_active IP Right Cessation
- 2003-02-26 AR ARP030100619A patent/AR038698A1/es unknown
- 2003-02-26 PE PE2003000187A patent/PE20030830A1/es not_active Application Discontinuation
-
2004
- 2004-07-15 ZA ZA200405635A patent/ZA200405635B/en unknown
- 2004-08-19 IS IS7417A patent/IS7417A/is unknown
- 2004-08-20 EC EC2004005242A patent/ECSP045242A/es unknown
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3432411A1 (de) * | 1983-09-17 | 1985-04-11 | Dr. Karl Thomae Gmbh, 7950 Biberach | Antiadhaesive prohylactica und arzneimittel, enthaltend ein sekretolytisch wirksames benzylaminderivat |
| DE3445226A1 (de) * | 1983-12-14 | 1985-08-01 | Reifenrath, Rainer Richard Otto, Dr.med., 7920 Heidenheim | Pharmazeutisches erzeugnis zur behandlung und prophylaxe von infektionen sowie von husten und obstruktiven atemwegserkrankungen |
| DE4415553A1 (de) * | 1994-05-03 | 1995-11-09 | Behringwerke Ag | Verwendung von Deoxyspergualin zur Herstellung eines Arzneimittels zur Behandlung von entzündlich-hyperreaktiven Erkrankungen |
| DE19933148A1 (de) * | 1999-07-20 | 2001-01-25 | Boehringer Ingelheim Int | Ambroxolhaltige Lutschtablette |
| DE20102817U1 (de) * | 2000-02-23 | 2001-06-07 | Bolder Arzneimittel GmbH, 50968 Köln | Lutsch- und Kaupastillen mit Cyclodextrin |
| WO2002045714A1 (en) * | 2000-12-04 | 2002-06-13 | The Procter & Gamble Company | Drug formulation having improved oral tolerability |
Non-Patent Citations (1)
| Title |
|---|
| Chemical Abstract Ref.111:167106, ISSN:0025-7931 * |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20040084944A (ko) | 2004-10-06 |
| RU2311176C2 (ru) | 2007-11-27 |
| MXPA04008220A (es) | 2004-11-26 |
| CA2477105A1 (en) | 2003-09-04 |
| PE20030830A1 (es) | 2003-10-31 |
| EP1480626A1 (de) | 2004-12-01 |
| TW200306804A (en) | 2003-12-01 |
| AU2003210345B2 (en) | 2009-01-29 |
| RU2004129284A (ru) | 2005-06-10 |
| JP2005518435A (ja) | 2005-06-23 |
| PL371584A1 (en) | 2005-06-27 |
| CN1638749A (zh) | 2005-07-13 |
| WO2003072094A1 (de) | 2003-09-04 |
| UA86741C2 (ru) | 2009-05-25 |
| UY27679A1 (es) | 2003-09-30 |
| AU2003210345A1 (en) | 2003-09-09 |
| AR038698A1 (es) | 2005-01-26 |
| ECSP045242A (es) | 2004-09-28 |
| BR0308038A (pt) | 2004-12-28 |
| IS7417A (is) | 2004-08-19 |
| MY144781A (en) | 2011-11-15 |
| ZA200405635B (en) | 2005-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69727000T2 (de) | Arzneimittel mit verzögerter Wirkstoffabgabe enthaltend Venlafaxin | |
| EP1067904B1 (de) | Feste, schnellzerfallende cetirizin-formulierungen | |
| DE69400435T2 (de) | Verwendung von carbamazepine und oxcarbazepine zur behandlung von parkinson und den parkinson-syndromen | |
| EP2613793B1 (de) | Nasenspray | |
| DE1667888C3 (de) | Langwirkende geformte pharmazeutische Zubereitungen | |
| CH655241A5 (de) | Verfahren zur herstellung therapeutisch wirksamer praeparate mit anhaltendem verlauf der wirkstoff-freisetzung. | |
| DE69027220T2 (de) | Zusammensetzung und verfahren zur behandlung von schmerzvollen entzündlichen oder allergischen erkrankungen | |
| DE69716947T2 (de) | Orale zusammenstellung die 5-aminosalicylsäure enthält | |
| DE10208313A1 (de) | Ambroxol für die Behandlung von schmerzhaften Zuständen im Mund und Rachenraum | |
| DE3786893T2 (de) | Piperidinderivat zur Schmerzbehandlung. | |
| US20100330176A1 (en) | Ambroxol for the treatment of painful conditions in the mouth and pharyngeal cavity | |
| EP0125634A1 (de) | Verwendung einer sekretolytisch wirkenden Substanz zur Herstellung eines Antischnarchmittels und zur Bekämpfung des Schnarchphänomens | |
| DE69411726T2 (de) | Zusammensetzungen zur freigabe einer aromatischen substanz in die nase | |
| DE10297329T5 (de) | Dexibuprofen enthaltende Weichgelatinekapseln und Verfahren zu ihrer Herstellung | |
| DE69030584T2 (de) | Verfahren sowie zusammensetzungen zur behandlung mit vitaminmineral | |
| DE69005160T2 (de) | Verwendung von 5'-Deoxy-5'-methylthioadenosin, s-Adenylmethionin und deren Salzen zur Herstellung pharmazeutischer Präparate zur Förderung des Haarwuchses bei Patienten mit Kahlköpfigkeit. | |
| DE69620786T2 (de) | Verwendung von cholinesterase-inhibitoren für die herstellung eines medikaments zur behandlung von xerostomie | |
| DE10338544B4 (de) | Buccale Formulierungen des Galanthamins und deren Anwendungen | |
| DE60216453T2 (de) | Verwendung von antidiabetika zur herstellung eines vernarbungsfördernden arzneimittels | |
| DE10354894A1 (de) | Orale Formulierungen des Desoxypeganins und deren Anwendungen | |
| DE19541815B4 (de) | Verwendung einer Lösung von Polyethylenglykol in Wasser als wässrige Spüllösung zur Prävention oder Behandlung von zähem Schleim, der in Verbindung mit Strahlen- oder/und Chemotherapie-induzierten Erkrankungen der Schleimhäute auftritt | |
| DE102021108264A1 (de) | Zusammensetzung zur topischen Anwendung an einem Subjekt | |
| DE3731528A1 (de) | Verwendung von trans-4- ((2-amino-3,5-dibrom-benzyl)-amino) -cyclohexanol zur lokalen behandlung von erkrankungen des auges | |
| DE19857716A1 (de) | Neue feste Formulierung von Metrifonat | |
| DE4225489A1 (de) | Verfahren zur Herstellung bioadhäsiver Augentropfen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OM8 | Search report available as to paragraph 43 lit. 1 sentence 1 patent law | ||
| 8141 | Disposal/no request for examination |